Long follow-up of symptomatic Multiple Myeloma patients after Covid-19 vaccination (BNT162b2): A single-institution retrospective experience

Mele Giuseppe; Romano Claudia; Miccoli Antonella; Santoro Angelo; Pastore Domenico

doi:10.1016/j.lrr.2022.100342

Long follow-up of symptomatic Multiple Myeloma patients after Covid-19 vaccination (BNT162b2): A single-institution retrospective experience

Leuk Res Rep. 2022:18:100342. doi: 10.1016/j.lrr.2022.100342. Epub 2022 Aug 8.

Authors

Mele Giuseppe¹, Romano Claudia¹, Miccoli Antonella², Santoro Angelo³, Pastore Domenico¹

Affiliations

¹ Haematology and Stem Cell Transplant Unit, Ospedale Antonio Perrino, Brindisi, Italy.
² Blood and Transfusion Medicine Department, Ospedale Antonio Perrino, Brindisi, Italy.
³ Laboratory Medicine Department, Ospedale Antonio Perrino, Brindisi, Italy.

Abstract

Myeloma patients are at an increased risk of severe forms of Covid-19. We examined response to mRNA vaccine between myeloma patients (n.127) and healthy volunteers (n.50). Anti-spike IgG antibody were detected in 76.9% of evaluable patients. 23.1% of MM patients failed to respond at two doses of COVID-19 mRNA vaccine. Univariate analyses identified three independent adverse predictive factors of absence of immunological response to COVID-19 vaccine: extreme plasmacytosis (p < 0.001), B2M (p 0.006), and haemoglobin (p 0.008). Multivariate analysis confirmed the extreme plasmacytosis and haemoglobin value as statistically significant variables.

Keywords: COVID-19 mRNA vaccine; Symptomatic multiple myeloma.